Consistently, the KEYNOTE-062 trial compared a first-line treatment with pembrolizumab alone or combined with chemotherapy to the standard chemotherapy in advanced HER2 negative GC or GEJC, selected for PD-L1 Combined Positive Score (CPS) ≥1 and ≥10. Here, ERBB2 is linked to gastric cancer.